Epiroc interim report Q1 2026

Orders rose 11% to MSEK 18,340, with 23% organic growth offset by a 12% currency headwind and large orders increasing to MSEK 1,280 from MSEK 280. Revenue fell 8% to MSEK 14,351, but adjusted operating profit held at MSEK 2,868 versus MSEK 3,099, with the adjusted margin essentially flat at 20.0%. The update is mixed: strong order intake and margin resilience, but lower sales and negative FX effects.

Analysis

The key takeaway is not the headline revenue decline; it is the divergence between bookings and sales, which usually signals either a delayed conversion cycle or a temporary delivery bottleneck. That is constructive for near-term backlog visibility and supports revenue stabilization over the next 1-2 quarters, but it also implies working capital could remain a drag until the order book is digested. The large-order mix suggests the company is leaning more on project-style demand, which can improve visibility but also raises lumpiness and execution risk.

Currency is doing a lot of the damage here, and that matters because FX is a cleaner reversal lever than underlying demand. If the company has natural hedges or pricing power, margins can re-rate faster than the market expects once the translation headwind abates; if not, the apparent margin resilience may be masking weaker local-currency pricing. The fact that adjusted margins held roughly flat despite lower reported sales suggests cost discipline is offsetting volume pressure, which is a positive signal for quality of earnings.

The second-order effect is competitive: peers with more domestic cost bases or better FX hedging should look relatively stronger on reported growth, even if underlying demand is similar. That creates a potential setup for a relative-value trade rather than a directional long — especially if investors are likely to overreact to the top-line decline without pricing in backlog conversion. The main risk is that this is not just a timing issue, but a sign that end-market demand is softening and orders are being pulled forward by a few large contracts; that would show up over the next 2-3 reporting periods through slower organic order growth and weaker conversion.

Consensus may be underestimating the resilience embedded in the order book and over-focusing on reported revenue weakness. If FX normalizes and those bookings convert at even a modest cadence, earnings can inflect faster than revenues because the margin base is already holding. The contrarian risk is that the market interprets this as a 'good orders, bad sales' story and bids the stock on backlog visibility, only to discover the large-order mix is low-quality or delayed, which would unwind quickly if the next quarter does not confirm conversion.

Key Decisions for Investors

• If this name sells off on the revenue miss, consider a tactical long into the next 2-6 weeks for a backlog-conversion rebound; risk/reward is favorable if orders convert and FX stops being a headwind, but reduce if the next update shows weaker organic bookings.
• Pair trade: long this industrial/engineering name against a peer with weaker order momentum and less FX support over the next 1-3 months; the cleaner relative catalyst is backlog conversion versus reported revenue noise.
• Sell downside via put spread into the next earnings cycle if implied volatility is elevated; the margin stability reduces crash risk unless order conversion deteriorates materially.
• If you are already long, hedge with a short basket of export-heavy cyclicals that are more exposed to currency translation, since reported growth dispersion is likely to be driven by FX rather than end-demand alone.